Cargando…

A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers

Our group recently developed a urinary 6-biomarker panel for the diagnosis of prostate cancer (PCa) which has a higher level of accuracy compared to the serum prostate specific antigen (PSA) test. Herein, urine from an independent cohort of PCa patients and cancer-free controls was analyzed to furth...

Descripción completa

Detalles Bibliográficos
Autores principales: Lima, Ana Rita, Pinto, Joana, Carvalho-Maia, Carina, Jerónimo, Carmen, Henrique, Rui, Bastos, Maria de Lourdes, Carvalho, Márcia, Guedes de Pinho, Paula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464354/
https://www.ncbi.nlm.nih.gov/pubmed/32717987
http://dx.doi.org/10.3390/cancers12082017
_version_ 1783577345552023552
author Lima, Ana Rita
Pinto, Joana
Carvalho-Maia, Carina
Jerónimo, Carmen
Henrique, Rui
Bastos, Maria de Lourdes
Carvalho, Márcia
Guedes de Pinho, Paula
author_facet Lima, Ana Rita
Pinto, Joana
Carvalho-Maia, Carina
Jerónimo, Carmen
Henrique, Rui
Bastos, Maria de Lourdes
Carvalho, Márcia
Guedes de Pinho, Paula
author_sort Lima, Ana Rita
collection PubMed
description Our group recently developed a urinary 6-biomarker panel for the diagnosis of prostate cancer (PCa) which has a higher level of accuracy compared to the serum prostate specific antigen (PSA) test. Herein, urine from an independent cohort of PCa patients and cancer-free controls was analyzed to further validate the discriminative power of that panel. Additionally, urine from patients diagnosed with bladder cancer (BC) and renal cancer (RC) were included to evaluate the site-specificity of the panel. Results confirmed the ability of the 6-biomarker panel to discriminate PCa patients from controls, but not from other urological cancers. To overcome this limitation, an untargeted approach was performed to unveil discriminant metabolites among the three cancer types. A 10-biomarker panel comprising the original panel plus four new metabolites was established to discriminate PCa from controls, BC, and RC, with 76% sensitivity, 90% specificity, and 92% accuracy. This improved panel also disclosed better accuracy than serum PSA test and provides the basis for a new non-invasive early detection tool for PCa.
format Online
Article
Text
id pubmed-7464354
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74643542020-09-04 A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers Lima, Ana Rita Pinto, Joana Carvalho-Maia, Carina Jerónimo, Carmen Henrique, Rui Bastos, Maria de Lourdes Carvalho, Márcia Guedes de Pinho, Paula Cancers (Basel) Communication Our group recently developed a urinary 6-biomarker panel for the diagnosis of prostate cancer (PCa) which has a higher level of accuracy compared to the serum prostate specific antigen (PSA) test. Herein, urine from an independent cohort of PCa patients and cancer-free controls was analyzed to further validate the discriminative power of that panel. Additionally, urine from patients diagnosed with bladder cancer (BC) and renal cancer (RC) were included to evaluate the site-specificity of the panel. Results confirmed the ability of the 6-biomarker panel to discriminate PCa patients from controls, but not from other urological cancers. To overcome this limitation, an untargeted approach was performed to unveil discriminant metabolites among the three cancer types. A 10-biomarker panel comprising the original panel plus four new metabolites was established to discriminate PCa from controls, BC, and RC, with 76% sensitivity, 90% specificity, and 92% accuracy. This improved panel also disclosed better accuracy than serum PSA test and provides the basis for a new non-invasive early detection tool for PCa. MDPI 2020-07-23 /pmc/articles/PMC7464354/ /pubmed/32717987 http://dx.doi.org/10.3390/cancers12082017 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Lima, Ana Rita
Pinto, Joana
Carvalho-Maia, Carina
Jerónimo, Carmen
Henrique, Rui
Bastos, Maria de Lourdes
Carvalho, Márcia
Guedes de Pinho, Paula
A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
title A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
title_full A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
title_fullStr A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
title_full_unstemmed A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
title_short A Panel of Urinary Volatile Biomarkers for Differential Diagnosis of Prostate Cancer from Other Urological Cancers
title_sort panel of urinary volatile biomarkers for differential diagnosis of prostate cancer from other urological cancers
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7464354/
https://www.ncbi.nlm.nih.gov/pubmed/32717987
http://dx.doi.org/10.3390/cancers12082017
work_keys_str_mv AT limaanarita apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT pintojoana apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT carvalhomaiacarina apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT jeronimocarmen apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT henriquerui apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT bastosmariadelourdes apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT carvalhomarcia apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT guedesdepinhopaula apanelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT limaanarita panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT pintojoana panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT carvalhomaiacarina panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT jeronimocarmen panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT henriquerui panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT bastosmariadelourdes panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT carvalhomarcia panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers
AT guedesdepinhopaula panelofurinaryvolatilebiomarkersfordifferentialdiagnosisofprostatecancerfromotherurologicalcancers